Skip to main content

Advertisement

SpringerLink
Log in

Lipid Effects of Psychiatric Medications

  • Nonstatin Drugs (WB Borden, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

People with schizophrenia have higher rates of medical illness and mortality than the general population. Cardiovascular disease is a major contributor to premature death in patients with schizophrenia. There has been an increase literature discussing the high prevalence of dyslipidemia, which is one of risk factors for cardiovascular disease, induced by second generation antipsychotic agents. Depression is associated with increased risks of diabetes, hypertension, cardiovascular disease. However, those may not be secondary to the use of antidepressant agents. In order to reduce the risk of cardiovascular disease in patients with schizophrenia receiving antipsychotic agents, obtaining fasting lipid measurements at regular intervals is needed. Further investigations are needed to evaluate the effects of antidepressive agents on lipid profiles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest that have been published recently are indicated as follows: • Of importance•• Of major importance

  1. Peet M. Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatr Suppl. 2004;47:S102–5.

    Article  Google Scholar 

  2. Gough SC, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol. 2005;19:47–55.

    Article  PubMed  Google Scholar 

  3. McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.

    Google Scholar 

  4. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.

    Article  PubMed  Google Scholar 

  5. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66:848–56.

    Google Scholar 

  6. Viron MJ, Stern TA. The impact of serious mental illness on health and healthcare. Psychosomatics. 2010;51:458–65.

    PubMed  Google Scholar 

  7. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatr. 1991;36:239–45.

    CAS  Google Scholar 

  8. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115–21.

    Article  PubMed  Google Scholar 

  9. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45:21–8.

    Article  PubMed  CAS  Google Scholar 

  10. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002;71:239–57.

    Article  PubMed  CAS  Google Scholar 

  11. Curkendall SM, Mo J, Glasser DB, et al. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatr. 2004;65:715–20.

    Article  Google Scholar 

  12. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

  13. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157:1835–42.

    Article  PubMed  CAS  Google Scholar 

  14. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatr Res. 2001;101:277–88.

    Article  CAS  Google Scholar 

  15. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–96.

    PubMed  CAS  Google Scholar 

  16. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatr. 1999;60:215–20.

    Article  CAS  Google Scholar 

  17. Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol. 2002;22:244–51.

    Article  PubMed  CAS  Google Scholar 

  18. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatr. 2001;62 Suppl 27:27–34. discussion 40–21.

    CAS  Google Scholar 

  19. Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care. 2003;26:1597–605.

    Article  PubMed  CAS  Google Scholar 

  20. Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697–701.

    Article  PubMed  CAS  Google Scholar 

  21. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatr. 1996;37:68–73.

    Article  CAS  Google Scholar 

  22. Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses—a comparison between different antipsychotic agents. Psychopharmacology (Berl). 2001;154:205–12.

    Article  CAS  Google Scholar 

  23. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157:975–81.

    Article  PubMed  CAS  Google Scholar 

  24. Pan A, Lucas M, Sun Q, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med. 2010;170:1884–91.

    Article  PubMed  Google Scholar 

  25. Patten SB, Williams JV, Lavorato DH, et al. Major depression as a risk factor for high blood pressure: epidemiologic evidence from a national longitudinal study. Psychosom Med. 2009;71:273–9.

    Article  PubMed  Google Scholar 

  26. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580–92.

    Article  PubMed  CAS  Google Scholar 

  27. • Pan A, Sun Q, Okereke OI, et al. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA. 2011;306:1241–9. They described the relationship between depressive disorder and cardiovascular disease.

    Article  PubMed  CAS  Google Scholar 

  28. Salaycik KJ, Kelly-Hayes M, Beiser A, et al. Depressive symptoms and risk of stroke: the Framingham Study. Stroke. 2007;38:16–21.

    Article  PubMed  Google Scholar 

  29. Shimbo D, Chaplin W, Crossman D, et al. Role of depression and inflammation in incident coronary heart disease events. Am J Cardiol. 2005;96:1016–21.

    Article  PubMed  Google Scholar 

  30. Strine TW, Mokdad AH, Dube SR, et al. The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. Gen Hosp Psychiatr. 2008;30:127–37.

    Article  Google Scholar 

  31. • Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67:220–9. They described the relationship between depressive disorder and cardiovascular disease.

    Article  PubMed  Google Scholar 

  32. Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005;91:465–71.

    Article  PubMed  CAS  Google Scholar 

  33. •• Liao CH, Chang CS, Wei WC, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res. 2011;126:110–6. It investigated the risks of developing diabetes mellitus, hypertension, and hyperlipidemia in treating schizophrenia with first and second generation antipsychotics. The effect of antipsychotic agents on lipid metabolism is a serious concern in psychiatric medication and their study is important.

  34. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatr. 2002;63:425–33.

    Article  CAS  Google Scholar 

  35. Patel JK, Buckley PF, Woolson S, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res. 2009;111:9–16.

    Article  PubMed  Google Scholar 

  36. Duncan EJ, Woolson SL, Hamer RM, et al. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. Int Clin Psychopharmacol. 2009;24:204–13.

    Article  PubMed  Google Scholar 

  37. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420–31.

    Article  PubMed  Google Scholar 

  38. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm. 1996;53:2079–81.

    PubMed  CAS  Google Scholar 

  39. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168:947–56.

    Article  PubMed  Google Scholar 

  40. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596–601.

    Google Scholar 

  41. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatr. 2004;49:753–60.

    Google Scholar 

  42. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19–32.

    Article  PubMed  Google Scholar 

  43. Mackin P, Bishop D, Watkinson H, et al. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry. 2007;191:23–9.

    Article  PubMed  Google Scholar 

  44. Watanabe J, Suzuki Y, Sugai T, et al. The lipid profiles in Japanese patients with schizophrenia treated with antipsychotic agents. Gen Hosp Psychiatr. 2012;34:525–8.

    Article  Google Scholar 

  45. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519–26.

    Article  PubMed  CAS  Google Scholar 

  46. de Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res. 2007;92:95–102.

    Article  PubMed  Google Scholar 

  47. Birkenaes AB, Birkeland KI, Engh JA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol. 2008;28:132–7.

    Article  PubMed  CAS  Google Scholar 

  48. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802–9.

    PubMed  Google Scholar 

  49. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005;4:193–205.

    Article  PubMed  CAS  Google Scholar 

  50. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2006;116:1813–22.

    Article  PubMed  CAS  Google Scholar 

  51. Domon SE, Webber JC. Hyperglycemia and hypertriglyceridemia secondary to olanzapine. J Child Adolesc Psychopharmacol. 2001;11:285–8.

    Article  PubMed  CAS  Google Scholar 

  52. Domon SE, Cargile CS. Quetiapine-associated hyperglycemia and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatr. 2002;41:495–6.

    Article  Google Scholar 

  53. Nguyen M, Murphy T. Olanzapine and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatr. 2001;40:133.

    Article  CAS  Google Scholar 

  54. Wetterling T. Hyperlipidemia--side-effect of the treatment with an atypical antipsychotic (zotepine)? Psychiatr Prax. 2002;29:438–40.

    Article  PubMed  Google Scholar 

  55. Jerrell JM, Tripathi A, Rizvi AA et al. The risk of developing type 2 diabetes mellitus associated with psychotropic drug use in children and adolescents: a retrospective cohort analysis. Prim Care Companion CNS Disord 2012, 14.

  56. • Pyykkonen AJ, Raikkonen K, Tuomi T, et al. Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: results from the PPP-Botnia Study. Ann Med. 2012;44:279–88. The relationship between depressive disorder and cardiovascular disease may not be driven by the use of antidepressive agents.

Download references

Disclosure

J. Watanabe: none.; Y. Suzuki: Received honoraria from Otsuka Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., GlaxoSmithKline K.K., and Eli Lilly Japan K.K.; T. Someya: Has grants/grants pending with MSD K.K., Asahal Kasel Pharma Cooperation, Astellas Pharma Inc., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eli Lilly Japan K.K., Pfizer Japan Inc., Meiji Seika Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Yoshitomiyakuhin Corp., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Novartis Pharma K.K., Abbott Japan Co., Ltd., Tsumura & Co.; received honoraria from MSD K.K., Asahi Kasei Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eli Lilly Japan K.K., Pfizer Japan Inc., Meiji Seika Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Yoshitomiyakuhin Corp., and Astellas Pharma Inc.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, 757 Asahimachidori-ichibancho, Chuo-ku, Niigata, 951-8510, Japan

    Junzo Watanabe, Yutaro Suzuki & Toshiyuki Someya

Authors
  1. Junzo Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yutaro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshiyuki Someya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiyuki Someya.

Additional information

This article is part of the Topical Collection on Nonstatin Drugs

Rights and permissions

Reprints and permissions

About this article

Cite this article

Watanabe, J., Suzuki, Y. & Someya, T. Lipid Effects of Psychiatric Medications. Curr Atheroscler Rep 15, 292 (2013). https://doi.org/10.1007/s11883-012-0292-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-012-0292-6

Keywords

Search

Navigation